Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Oncology and Therapy
Published in: Oncology and Therapy 1/2024

Open Access 01-02-2024 | Acute Myeloid Leukemia | Review

Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation

Author: Xavier Thomas

Published in: Oncology and Therapy | Issue 1/2024

Login to get access

Abstract

Recent advances have included insights into the clinical value of genomic abnormalities in acute myeloid leukemia (AML) and consequently the development of numerous targeted therapeutic agents that have improved clinical outcome. In this setting, various clinical trials have recently explored novel therapeutic agents either used alone or in combination with intensive chemotherapy or low-intensity treatments. Among them, menin inhibitors could represent a novel group of targeted therapies in AML driven by rearrangement of the lysine methyltransferase 2A (KMT2A) gene, previously known as mixed-lineage leukemia (MLL), or by mutation of the nucleophosmin 1 (NPM1) gene. Recent phase 1/2 clinical trials confirmed the efficacy of SNDX-5613 (revumenib) and KO-539 (ziftomenib) and their acceptable tolerability. Several small molecule menin inhibitors are currently being evaluated as a combination therapy with standard of care treatments. The current paper reviews the recent progress in exploring the inhibitors of menin–KMT2A interactions and their application prospects in the treatment of acute leukemias.
Literature
1.
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1346–77.CrossRef
2.
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with FLT3 mutation. N Engl J Med. 2017;377:454–64.PubMedPubMedCentralCrossRef
3.
Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicenter, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18:1061–75.PubMedPubMedCentralCrossRef
4.
Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019;133:676–87.PubMedPubMedCentralCrossRef
5.
DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386–98.PubMedCrossRef
6.
Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase 1b/2 study. J Clin Oncol. 2019;37:1277–84.PubMedPubMedCentralCrossRef
7.
DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.PubMedPubMedCentralCrossRef
8.
Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379–89.PubMedCrossRef
9.
Issa GC, Ravandi F, DiNardo CD, et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35:2482–95.PubMedCrossRef
10.
Yokoyama A, Somervaille TC, Smith KS, et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123:207–18.PubMedCrossRef
11.
Caslini C, Yang Z, El-Osta M, et al. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 2007;67:7275–83.PubMedPubMedCentralCrossRef
12.
Murai MJ, Chruszcz M, Reddy G, et al. Chrystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J Biol Chem. 2011;286:31742–8.PubMedPubMedCentralCrossRef
13.
Huang J, Gurung B, Wan B, et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature. 2021;482:542–6.ADSCrossRef
14.
Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7:823–33.PubMedCrossRef
15.
Uckelmann HJ, Kim SM, Wong EM, et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020;367:586–90.ADSPubMedPubMedCentralCrossRef
16.
Klossowski S, Miao H, Kempinska K, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020;130:981–97.PubMedPubMedCentralCrossRef
17.
Shi Q, Xu M, Kang Z, et al. Menin-MLL1 interaction small molecule inhibitors: a potential therapeutic strategy for leukemia and cancers. Molecules. 2023;28:3026.PubMedPubMedCentralCrossRef
18.
He S, Senter TJ, Pollock J, et al. High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. J Med Chem. 2014;57:1543–56.PubMedPubMedCentralCrossRef
19.
Xu S, Aguilar A, Xu T, et al. Design of the first-in-class, highly potent irreversible inhibitor targeting the menin-MLL protein-protein interaction. Angew Chem Int Ed Engl. 2018;57:1601–5.PubMedCrossRef
20.
Xu S, Aguilar A, Huang L, et al. Discovery of M-808 as a highly potent, covalent, small-molecule inhibitor of the menin-MLL interaction with strong in vivo anti-tumor activity. J Med Chem. 2020;63:4997–5010.PubMedPubMedCentralCrossRef
21.
Aguilar A, Zheng K, Xu T, et al. Structure-based discovery of M-89 as a highly potent inhibitor of the menin-mixed lineage leukemia (menin-MLL) protein-protein interaction. J Med Chem. 2019;62:6015–34.PubMedPubMedCentralCrossRef
22.
Borkin D, He S, Miao H, et al. Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015;27:589–602.PubMedPubMedCentralCrossRef
23.
Zhang M, Aguilar A, Xu S, et al. Discovery of M-1121 as an orally active covalent inhibitor of menin-MLL interaction capable of achieving complete and long-lasting tumor regression. J Med Chem. 2021;64:10333–49.PubMedPubMedCentralCrossRef
24.
Pollock J, Borkin D, Lund G, et al. Rational design of orthogonal multipolar interactions with fluorine in protein-ligand complexes. J Med Chem. 2015;58:7465–74.PubMedPubMedCentralCrossRef
25.
Rozovskaia T, Feinstein E, Mor O, et al. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4;11) abnormality. Oncogene. 2001;20:874–8.PubMedCrossRef
26.
Zhou H, Liu L, Huang J, et al. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. J Med Chem. 2013;56:1113–23.PubMedCrossRef
27.
Swaminathan M, Bourgeois W, Armstrong SA, et al. Menin inhibitors in acute myeloid leukemia—what does the future hold? Cancer J. 2022;28:62–6.PubMedCrossRef
28.
Meyer C, Kowarz E, Hofmann J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009;23:1490–9.PubMedCrossRef
29.
Richard-Carpentier G, Kantarjian HM, Tang G, et al. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021;5:5415–9.PubMedPubMedCentralCrossRef
30.
Krivtsov AV, Evans K, Gadrey JY, et al. A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell. 2019;36:660–73.PubMedPubMedCentralCrossRef
31.
Yu BD, Hess JL, Horning SE, et al. Altered Hox expression and segmental identity in Mll-mutant mice. Nature. 1995;378:505–8.ADSPubMedCrossRef
32.
Chandrasekharappa S, Guru S, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404–7.PubMedCrossRef
33.
La P, Desmond A, Hou Z, et al. Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. Oncogene. 2006;25:3537–46.PubMedCrossRef
34.
Dreijerink KMA, Timmers HTM, Brown M. Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1. Endocr-Relat Cancer. 2017;24:T135-145.PubMedPubMedCentralCrossRef
35.
Li BE, Gan T, Meyerson M, et al. Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood. 2013;122:2039–46.PubMedPubMedCentralCrossRef
36.
37.
Kühn MW, Song E, Feng Z, et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 2016;6:1166–81.PubMedPubMedCentralCrossRef
38.
39.
40.
Wang ES, Altman JK, Pettit K, et al. Preliminary data on a phase 1/2A first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia. Blood. 2020;136:7–8.CrossRef
41.
McGeehan J. Q first-in-class menin-MLL1 antagonist for the treatment of MLL-r and NPM1 mutant leukemias. In: Proc 111th Annual Meeting of the American Association for Cancer Research 2020; abstract DDT01-01.
42.
43.
Aldoss I, Issa GC, Thirman M, et al. Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: efficacy and safety results from the Augment-101 phase 1/2 study. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 2907.
44.
Zucenka A, Issa GC, Martha Arellano M, et al. Revumenib maintenance therapy following revumenib-induced remission and transplant. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 4950.
45.
Daver N, Zeidner JF, Yuda J, et al. Phase 1/2 first-in-Human study of the menin-MLL inhibitor DSP-5336 in patients with relapsed or refractory acute leukemia. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 2911.
46.
Jabbour E, Searle E, Abdul-Hay M, et al. A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 57.
47.
Ravandi F, Kishtagari A, Carraway HE, et al. COVALENT-101: a phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B cell lymphoma (DLBCL), and multiple myeloma (MM). J Clin Oncol. 2022;40(suppl):abstract TPS7064.CrossRef
48.
Lancet J, Ravandi F, Montesinos P, et al. Covalent menin inhibitor Bmf-219 in patients with relapsed or refractory (R/R) acute leukemia (AL): preliminary phase 1 data from the Covalent-101 study. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 2916.
49.
Fiskus W, Boettcher S, Daver N, et al. Effective menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022;12:5.PubMedPubMedCentralCrossRef
50.
Sharma R, Frigault MM, Johnson AJ, et al. Targeting CDK9 in KMT2A-rearranged infant leukemia: evidence for activity and drug synergy with enitociclib. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 4293.
51.
Zeidan A, Fathi A, Issa G, et al. KOMET-007 trial in progress: a phase I study of ziftomenib in combination with venetoclax or venetoclax/azacitidine, or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib, for the treatment of patients with acute myeloid leukemia. Clin Lymph Myel Leuk. 2023;9:S308-309.CrossRef
52.
Scheidegger N, Alexe G, Khalid D, et al. Combining menin and MEK inhibition to target poor prognostic KMT2A-rearranged RAS pathway-mutant acute leukemia. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 166.
53.
Uddin H, Aboukameel A, Siddiqui SH, et al. The clinical menin inhibitor ziftomenib and the nuclear export inhibitor selinexor synergistically inhibit the growth of MLL-r AML. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 4158.
54.
Goldberg AD, Corum D, Ahsan J, et al. Komet-008: a phase 1 study to determine the safety and tolerability of ziftomenib combinations for the treatment of KMT2A-rearranged or NPM1-mutant relapsed/refractory acute myeloid leukemia. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 1553.
55.
Issa GC, Cuglievan B, DiNardo CD, et al. Early results of the phase I/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE). In: 65th American Society of Hematology Annual Meeting 2023; Abstract 58.
56.
Ciaurro V, Konopleva MY, Daver N, et al. Synergistic growth inhibition of NPM1 mutant AML PDX by combined therapy with BCL-2 inhibitor venetoclax (ABT-199) and menin inhibitor DS-1594b in vivo. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 4169.
57.
Fathi AT, Stein EM, DiNardo CD, et al. Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. Am J Hematol. 2021;96:735–46.PubMedCrossRef
58.
Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019;187:157–62.PubMedCrossRef
59.
Zhou X, Zhang L, Aryal S, et al. Decoding the epigenetic drivers of menin-MLL inhibitor resistance in KMT2A-rearranged acute myeloid leukemia. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 587.
60.
Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536–51.PubMedPubMedCentralCrossRef
61.
Shi X, Li M, Tan L, et al. Purine metabolism modulates leukemia stem cell maintenance in MLL-rearranged acute leukemia. In: 65th American Society of Hematology Annual Meeting 2023; Abstract 582.
Metadata
Title
Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation
Author
Xavier Thomas
Publication date
01-02-2024
Publisher
Springer Healthcare
Published in
Oncology and Therapy / Issue 1/2024
Print ISSN: 2366-1070
Electronic ISSN: 2366-1089
DOI
https://doi.org/10.1007/s40487-024-00262-x

Other articles of this Issue 1/2024

Oncology and Therapy 1/2024 Go to the issue

Editorial

From Incidence to Intervention: A Comprehensive Look at Breast Cancer in South Africa

Original Research

A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario

Original Research

Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience

Correction

Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer

Original Research

Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors

Commentary

Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits